INTELLIA THERAPEUTICS INC (NTLA) Stock News
NASDAQ:NTLA - Nasdaq - US45826J1051 - Common Stock - Currency: USD
NTLA Latest News, Press Relases and Analysis
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in...
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Cava: Rapid Growth but Some Concerns
Fast-casual restaurant company Cava reported revenue and earnings that handily beat expectations. Same-restaurant sales growth of 10.8% was especially impressive. The company's forecast calls for same-restaurant sales growth to decelerate as the year goes on.
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall in after-hours trading.
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 12.70% and 14.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BFRI
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress
On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the...
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y
PRGO reports mixed first-quarter 2025 results. The top line declines, largely due to the loss of sales stemming from exited businesses and product lines.
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 22.92% and 103.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CCCC
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of 20% and 8.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CRMD
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: OBIO
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: KRYS
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite stocks.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite stocks.
Why Viking Therapeutics Stock Popped Again Today
Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock.
Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 392.8% in Intellia Therapeutics (NTLA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation
/PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA)....
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:...
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA
/PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Intellia Therapeutics ("Intellia" or "the Company") (NASDAQ: NTLA) for...